Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
Michael Karbiener, Maria R. Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori, Alexander R. Moschen, Thomas R. Kreil
Abstract
SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and a vector-based (Vaxzevria) COVID-19 vaccine, calibrated against the WHO international SARS-CoV-2 antibody standard, and further supports the use of neutralizing antibody levels as a correlate of protection.
Topics & Concepts
VirologyNeutralizing antibodyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyAntibody response2019-20 coronavirus outbreakMessenger RNASars virusBiologyMedicineImmunologyVirusGeneOutbreakInfectious disease (medical specialty)GeneticsDiseasePathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral gastroenteritis research and epidemiology